111 related articles for article (PubMed ID: 12583549)
1. The integration of four major determinants of antibiotic action: bactericidal activity, postantibiotic effect, susceptibility, and pharmacokinetics.
Li RC; Zhu ZY
J Chemother; 2002 Dec; 14(6):579-83. PubMed ID: 12583549
[TBL] [Abstract][Full Text] [Related]
2. Impact of pharmacokinetics on the postantibiotic effect exhibited by Pseudomonas aeruginosa following tobramycin exposure: application of an in-vitro model.
Zhu ZY; Li RC
J Antimicrob Chemother; 1998 Jul; 42(1):61-5. PubMed ID: 9700529
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activity of subinhibitory concentrations of aminoglycosides against Pseudomonas aeruginosa as determined by the killing-curve method and the postantibiotic effect.
Zhanel GG; Karlowsky JA; Hoban DJ; Davidson RJ
Chemotherapy; 1991; 37(2):114-21. PubMed ID: 1903340
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic exposure and its relationship to postantibiotic effect and bactericidal activity: constant versus exponentially decreasing tobramycin concentrations against Pseudomonas aeruginosa.
Li RC; Zhu ZY; Lee SW; Raymond K; Ling JM; Cheng AF
Antimicrob Agents Chemother; 1997 Aug; 41(8):1808-11. PubMed ID: 9257767
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.
Tessier PR; Nicolau DP; Onyeji CO; Nightingale CH
Chemotherapy; 1999; 45(4):284-95. PubMed ID: 10394012
[TBL] [Abstract][Full Text] [Related]
6. Correlation between bactericidal activity and postantibiotic effect for five antibiotics with different mechanisms of action.
Li RC; Lee SW; Kong CH
J Antimicrob Chemother; 1997 Jul; 40(1):39-45. PubMed ID: 9249203
[TBL] [Abstract][Full Text] [Related]
7. The influence of postantibiotic effects and postantibiotic effects of sub-inhibitory concentrations of quinolones and aminoglycosides on phospholipase C of Pseudomonas aeruginosa.
Hybenová D; Majtán V
Pharmazie; 1997 Feb; 52(2):157-9. PubMed ID: 9122276
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic modeling and simulation for bactericidal effect in an in vitro dynamic model.
Katsube T; Yano Y; Yamano Y; Munekage T; Kuroda N; Takano M
J Pharm Sci; 2008 Sep; 97(9):4108-17. PubMed ID: 18314887
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance.
Schentag JJ
J Chemother; 1999 Dec; 11(6):426-39. PubMed ID: 10678784
[TBL] [Abstract][Full Text] [Related]
10. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
[TBL] [Abstract][Full Text] [Related]
11. Alteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinetic model.
den Hollander JG; Mouton JW; van Goor MP; Vleggaar FP; Verbrugh HA
Antimicrob Agents Chemother; 1996 Mar; 40(3):784-6. PubMed ID: 8851612
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model.
Katsube T; Yamano Y; Yano Y
J Pharm Sci; 2008 Apr; 97(4):1606-14. PubMed ID: 17705288
[TBL] [Abstract][Full Text] [Related]
13. Duration and clinical relevance of postantibiotic effect in relation to the dosing interval.
den Hollander JG; Fuursted K; Verbrugh HA; Mouton JW
Antimicrob Agents Chemother; 1998 Apr; 42(4):749-54. PubMed ID: 9559777
[TBL] [Abstract][Full Text] [Related]
14. [Effect of tobramycin on characteristics of strains of Acinetobacter species].
Hostacká A
Ceska Slov Farm; 2003 Jul; 52(4):193-7. PubMed ID: 12924072
[TBL] [Abstract][Full Text] [Related]
15. Urinary concentrations and antimicrobial activity of tobramycin in healthy volunteers receiving a single oral dose of a novel formulation for improved absorption.
Loose M; Naber KG; Shields P; Reinhart H; Wagenlehner FME
Int J Antimicrob Agents; 2018 Mar; 51(3):422-426. PubMed ID: 29158143
[TBL] [Abstract][Full Text] [Related]
16. Antibiotic penetration and bacterial killing in a Pseudomonas aeruginosa biofilm model.
Cao B; Christophersen L; Thomsen K; Sønderholm M; Bjarnsholt T; Jensen PØ; Høiby N; Moser C
J Antimicrob Chemother; 2015 Jul; 70(7):2057-63. PubMed ID: 25786481
[TBL] [Abstract][Full Text] [Related]
17. [In vitro bactericidal activity of tobramycin and amikacin alone or in combination against Pseudomonas aeruginosa isolated from patients with cystic fibrosis].
Bertrou A; Marty N; Henry S; Agueda L; Chabanon G
Pathol Biol (Paris); 1990 May; 38(5):366-75. PubMed ID: 2114606
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of beta-lactam antibiotics. Studies on the paradoxical and postantibiotic effects in vitro and in an animal model.
Odenholt-Tornqvist I
Scand J Infect Dis Suppl; 1989; 58():1-55. PubMed ID: 2499924
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of in vitro synergy between vertilmicin and ceftazidime against Pseudomonas aeruginosa using a semi-mechanistic pharmacokinetic/pharmacodynamic model.
Zhuang L; Sy SK; Xia H; Singh RP; Mulder MB; Liu C; Derendorf H
Int J Antimicrob Agents; 2015 Feb; 45(2):151-60. PubMed ID: 25465523
[TBL] [Abstract][Full Text] [Related]
20. Changes in MIC alter responses of Pseudomonas aeruginosa to tobramycin exposure.
Ioannides-Demos LL; Liolios L; Wood P; Spicer WJ; McLean AJ
Antimicrob Agents Chemother; 1998 Jun; 42(6):1365-9. PubMed ID: 9624477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
